



This is a repository copy of *Lung cancer in never smokers (LCINS): development of a UK national research strategy*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/216442/>

Version: Published Version

Article:

Khan, S., Hatton, N., Tough, D. et al. (12 more authors) (2023) Lung cancer in never smokers (LCINS): development of a UK national research strategy. *BJC Reports*, 1 (1). 21. ISSN 2731-9377

<https://doi.org/10.1038/s44276-023-00006-w>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

REVIEW OPEN



Lung cancer in never smokers (LCINS): development of a UK national research strategy

Sam Khan^{1,16}, Nathaniel Hatton^{2,16}, Daniel Tough^{3,16}, Robert C. Rintoul⁴, Coral Pepper⁵, Lynn Calman⁶, Fiona McDonald⁷, Clare Harris⁸, Amelia Randle⁹, Michelle C. Turner¹⁰, Ruth A. Haley¹¹, Janette Rawlinson¹², Philip A. J. Crosbie^{13,17}, Frank McCaughan^{14,17} and Matthew Hatton^{15,17}✉

© The Author(s) 2023

INTRODUCTION: Lung cancer in never smokers (LCINS) accounts for 15% of lung cancers diagnosed in the UK, making it the 8th most common cancer. There are few robust studies specific to the LCINS population making data surrounding the incidence and mortality of LCINS incomplete, leaving many gaps in our understanding of the needs of this population.

METHODS: To address a lack of research in this important area, the UK National Cancer Research Institute Lung Study Group (NCRI-LSG) undertook a national survey and hosted a research strategy day to define key research priorities. A wide cross section of stakeholders, including patient advocates, the charitable sector, basic and translational researchers, and multi-disciplinary healthcare professionals contributed highlighting their research priorities.

RESULTS: One-hundred twenty-seven surveys were completed (52 by patients/patient advocates) prior to the strategy day. These identified themes for expert review presentations and subsequent workshop discussions at the national research strategy day, which registered 190 attendees (50 patients/patient advocates). The four key themes that emerged to form the basis of a research strategy for LCINS are (1) Raising awareness, (2) Risk assessment and early detection, (3) Disease biology, (4) Living with and beyond.

CONCLUSION: This paper summarises current evidence and important gaps in our knowledge related to LCINS. We present recommendations for a national research strategy aimed at improving outcomes for patients.

BJC Reports; <https://doi.org/10.1038/s44276-023-00006-w>

INTRODUCTION

Lung cancer is the world's leading cause of cancer-related death and it is estimated that 10–25% of all diagnoses are made in individuals who have never smoked [1]. Lung cancer in never smokers (LCINS) is the 7th leading cause of cancer death for men and women worldwide [2]. The widely accepted definition of a 'never-smoker' (NS) is an individual who has smoked less than 100 cigarettes in their lifetime [3]. In the UK, LCINS is responsible for an estimated 6000 deaths per year making LCINS the 8th most common cancer in the UK if considered as a distinct disease entity [4]. The demographic of LCINS differs significantly from lung cancer occurring in the smoking population; the majority of cases occurring in women [5], presenting at a younger age [6, 7] commonly adenocarcinomas [3] with significantly higher frequencies of driver mutations [8]. For the majority of LCINS symptoms are non-specific [9], often dismissed by patients and primary healthcare providers, meaning patients have advanced disease at presentation [10] with a significant proportion diagnosed at

emergency presentation [11]. Although, survival for LCINS appears better than for the smoking population in prospective studies, it remains disappointingly low [12].

There are few robust studies specific to the LCINS population making data surrounding the incidence and mortality of LCINS incomplete, leaving many gaps in our understanding of the needs of this population. A review of the UK Lung Cancer trial portfolio (January 2023) showed that of 150 'open' studies none are exclusively focused on the LCINS population. Having identified the paucity of specific research focused on LCINS the Steering Committee of the National Cancer Research Institute's Lung Group (NCRI-LG) recognised that specific needs of this population are likely to be different to the smoking lung cancer populations and set out to understand those needs through a survey and research strategy day. Recognising that they may be specific needs at all stages of the patient journey we elected to take an open approach using responses to the on-line survey taking specific needs highlighted by multiple responders forward for a

¹Leicester Cancer Research Centre, University of Leicester, Leicester, UK. ²Division of Oncology, Leeds Teaching Hospital Trust, Leeds, UK. ³Department of Education, Health and Lifelong Learning, Bishop Grosseteste University, Lincoln, UK. ⁴Department of Oncology, Royal Papworth Hospital, University of Cambridge, Cambridge, UK. ⁵Library and Information Services, University Hospitals of Leicester NHS Trust, Leicester, UK. ⁶Centre for Psychosocial Research in Cancer, School of Health Sciences, University of Southampton, Southampton, UK. ⁷Department of Oncology, Royal Marsden's Hospital, London, UK. ⁸Department of Medicine, University of Cambridge, Cambridge, UK. ⁹Somerset, Wiltshire, Avon and Gloucestershire Cancer alliance, Cambridge, UK. ¹⁰Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain. ¹¹Formerly National Cancer Research Institute (NCRI), Madrid, Spain. ¹²Patient representative, Sandwell, UK. ¹³Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK. ¹⁴Heart and Lung Research Institute, Department of Medicine, University of Cambridge, Cambridge, UK. ¹⁵Weston Park Hospital, Sheffield Teaching Hospital Trust, Sheffield, UK. ¹⁶These authors contributed equally: Sam Khan, Nathaniel Hatton, Daniel Tough. ¹⁷These authors jointly supervised this work: Philip A. J. Crosbie, Frank McCaughan, Matthew Hatton. ✉email: matthewhatton@nhs.net

Received: 5 April 2023 Revised: 19 June 2023 Accepted: 28 June 2023

Published online: 20 July 2023

more detailed review on the strategy day. We have structured this report around 4 key themes identified through this process.

METHODS

The NCRI-LG undertook a survey and a one-day meeting to review and identify evidence gaps for the diagnosis and management of LCINS. The potential for evidence gaps to exist across the patient journey from diagnosis through to survivorship was recognised. An open approach was taken with the survey used to prioritise potential research questions for workshops within a meeting to formulate the research strategy for the NCRI-LG, which will be developed into workstreams to inform and design future studies focusing on improving outcomes for patients.

A bespoke survey was designed to collate ideas for research questions (Appendix A). The survey contained 6 categories (basic science, prevention, screening/early detection, diagnosis, treatment and survivorship). Within each of those categories, respondents were asked to list their top 5 research questions. The outcomes of the survey were grouped to formulate the workshop agenda (Appendix B) and discussion topics for breakout sessions (Appendix C).

Attendance was open to the UK lung cancer community and invitations were circulated through the multi-disciplinary professional bodies (including NCRI newsletters and study groups, the British Thoracic Oncology Group (BTOG)), patient organisations (NCRI patient forum, NCRI partner charities and UK lung cancer-specific charities) and social media. Those registering interest completed a survey to highlight their research priorities prior to the meeting. The results were used to identify themes for the workshops to explore in greater detail. The meeting was held virtually in May 2021. Participants (Table 1) were assigned to two workshops, Early Detection or Treatment, with discussion moderated to cover discovery/biology, Living with and Beyond Cancer (LWBC) and clinical research focusing on patient outcomes. The discussions were recorded, transcribed and collated with data from the survey by members of the NCRI secretariat to produce themes centred around the unmet needs of the LCINS population and research priorities. A further survey came after the strategy day, for individuals to choose their top three research questions. An average ranking of results was used to obtain the order of priorities. The themes are presented with background information and recommendations for research.

THEME 1: RAISING AWARENESS

Patient and public comments

Raising awareness of LCINS, reducing barriers and delays to diagnosis were repeatedly highlighted from the surveys as an area

Table 1. Outline of registered delegates ($N = 190$) and breakdown of those completing survey ($N = 127$).

Breakdown of delegates	Number of participants
Total registered—strategy day	190
Total—completed survey	127
Breakdown of those completing survey	Number of participants
Patient advocates	52
Clinicians/consultants or academics	27
Allied health professionals	15
Scientists	14
Students or early career researchers	7
Government, charity or research managers	5
Industry	4
Unknown	3

which should be prioritised—‘*Much more awareness is needed both in the medical profession and general public*’. Attendees believed that more is needed to reduce the stigma surrounding lung cancer—‘*the respiratory doctor asked if I was a heavy smoker but I am a fifty year old never smoker*’, whilst highlighting the symptoms of the disease to aid quicker diagnoses—

‘It needs to be stressed that vague symptoms can be cancer’. ‘Many of the (LCINS) patients I’ve met, like me had some sort of history of repeated chest infections yet were sent away with inhalers, antibiotics, steroids over a considerable time—many more had treated themselves for their non-specific symptoms by over-the-counter remedies bought in supermarkets or pharmacies. Several were told by their GP that their symptoms may be menopause.’

Evidence

The earlier detection of symptomatic cancer in general is associated with improved patient outcomes although there are no specific data available for individuals with LCINS [13]. 70% of patients who are diagnosed with cancer first report symptoms to Primary Care [14]. There are several factors that contribute to the delayed presentation of symptomatic lung cancer related to primary care/the healthcare system, the patient and the disease [15, 16]. Symptoms commonly associated with lung cancer, such as cough and breathlessness, are non-specific [17]. This can make it challenging for healthcare professionals to identify those patients requiring immediate investigation [18], which can lead to diagnostic delay [19]. In one study, a quarter of lung cancer diagnoses involved an avoidable delay and one third required three or more consultations with their GP prior to specialist referral [20, 21]. A higher number of pre-referral consultations is associated with a more negative experience of cancer care [22].

Clinical presentation. Little research has examined the clinical presentation of LCINS [23]. Retrospective series suggest symptoms are similar irrespective of smoking status, although haemoptysis may be less frequent in never smokers [9, 24]. There is some evidence that never smokers have more advanced disease at diagnosis [3, 24, 25] but this is not a consistent finding [26]. The widely known link between smoking and lung cancer may inadvertently lead patients who have never smoked and healthcare professionals to attribute symptoms to other causes [27]. In one study, never smokers took longer to seek medical attention compared to ever smokers (3 versus 2 months) [24] though this finding was not replicated in another study [28]. Despite this never smokers with lung cancer are reported to have better survival than smokers [12, 25, 26, 29–31]. The anecdotal nature of evidence around the clinical presentation of lung cancer in never smokers, where first symptoms can be a small change in ‘sporting’ performance, represents a very important gap in our knowledge.

LCINS awareness. Raising public awareness of LCINS through a media campaign is one approach that could reduce the delay in patients reporting symptoms. The potential benefit of such an approach was demonstrated by an increase in early lung cancer detection following a national awareness campaign highlighting persistent cough (3 weeks or longer) as a possible symptom of lung cancer. A public and healthcare professional lung cancer symptom awareness campaign in Leeds increased chest X-ray referral rates and the detection of early-stage disease [32]. A study in Doncaster combining a community-based social marketing intervention with GP education also had a positive impact on lung cancer detection [33]. It is unknown whether an education/awareness campaign specifically focused on LCINS would have an equivalent impact [34].

Recommendations

- Develop interventions to raise awareness of LCINS at local, regional and national level. Interventions should include educational resources to improve knowledge about LCINS for healthcare professionals, in an accessible format for the public. There should be explicit information that anyone can get Lung Cancer and prior good health, diet and exercise capacity does not preclude the diagnosis.
- Interventions and educational resources used to improve awareness should be co-designed by key stakeholders including those with lived experience of LCINS. To help prompt referral and investigations for an alternative diagnosis if the clinical presentation is atypical.
- Interventions should be designed to ensure equity of access to information irrespective of age, sex, race, digital access and geographical locality. In practice this will require innovation in communication with the general population
- Further research is needed to explore the patient journey from development of symptoms to diagnosis of LCINS to identify factors/barriers to earlier presentation.

THEME 2: RISK ASSESSMENT AND EARLY DETECTION

Patient and public comments

A critical question raised by patients is ‘why me?’, given the much-emphasised direct association between smoking and lung cancer and the stigma associated with the disease. A clearer understanding of the risk factors for LCINS would have a major impact on raising awareness, avoiding risk and the development of screening protocols for the early detection of LCINS in the UK. Participants suggested the implementation of routine screening following identification of risk factors of LCINS to detect the disease when at its most treatable, improving survival rates—

‘Is it possible to produce a health app which prompts a number of regular screening questions, which would advise seeking appropriate medical advice?’.

To achieve this, we need research programmes that comprehensively assess germline (inherited) risk, the impact of respiratory comorbidities, environmental and occupational exposures, and the molecular pathobiology of LCINS. Given the difficulties in identifying these risk factors, one participant questioned the feasibility of screening for lung cancer in never smokers, suggesting the focus should be upon education—‘*Can we realistically even consider screening for lung cancer in never smokers, should the focus be on education and awareness, so that concerns about lung cancer symptoms in never-smokers are not so frequently dismissed...*’.

This highlights the disparity between current knowledge and an idealistic early screening assessment.

Evidence

Risk factors

Environmental exposures: Several environmental exposures are associated with increased risk of developing LCINS. Such exposures may be related to a person’s location, occupation, methods of cooking or heating and exposure to environmental tobacco smoke (passive smoking) [35, 36]. Living in an area with high background levels of radon is associated with an increased risk of developing lung cancer [37–39]. There is strong evidence that pollution, specifically particulate matter in outdoor air pollution, is carcinogenic in humans [40, 41] accounting for some of the global lung cancer incidence [42]. Higher ambient particulate matter (PM_{2.5}) exposures were associated with higher lung cancer mortality in never smokers [43]. Other lung cancer risk factors include indoor emissions from household coal combustion, asbestos, silica dust,

arsenic, welding fumes, diesel engine exhaust, various metals and other occupational processes [44–46]. Recently opium consumption was classified as carcinogenic for lung cancer [47].

Several gaps in our knowledge remain including interactions of environmental and occupational agents, identification of vulnerable exposure time windows or subpopulations, or in the case of complex exposures, identification of the most relevant or responsible agent [45, 48–50]. Occupational agents have typically been understudied in women [51]. There is a range of other environmental and occupational agents where the strength of the evidence in humans remains limited [52]. Little is known regarding the impact of exposure to environmental and occupational agents on lung cancer survival post diagnosis. Information on the effectiveness of specific interventions for cancer prevention is also often scarce.

Genetic susceptibility: LCINS is more common in females and in some ethnic groups [53, 54]. The female preponderance is poorly understood but is maintained across different ethnicities and national cohorts from South-East Asia to the US. In a large prospective study of women in the UK, risk factors for the development of LCINS included non-white ethnicity, asthma requiring treatment and taller stature [55]. A potential role for oestrogen has been mooted but the evidence is mixed, the prospective UK study did not show any link to the age of menopause or post-menopausal use of hormonal therapies [55]. In general, epithelial malignancies increase with age but LCINS is typically associated with a younger demographic than that of the smoking lung cancer population [24, 56–58].

The genetic predisposition to lung cancer has been well studied and multiple genetic loci/single-nucleotide polymorphisms associated with lung cancer risk [59]. More recently studies have examined germline risk in LCINS, particularly in Asian cohorts. There are both shared loci between smokers and never-smokers and distinct loci that segregate with LCINS or ever-smoker lung cancer. It is not clear how these findings translate to a UK population. A study in a Chinese population demonstrated how a polygenic risk score developed using SNPs could stratify individuals (including never smokers) according to lung cancer risk [60]. One interesting germline risk is the inherited SNP associated with the T970M mutation in EGFR, a mutation, which confers resistance to EGFR-specific tyrosine kinase inhibitors. This risk allele has been reported in US and in Asian cohorts [61–65]. There is an obvious need to understand the potential contribution of germline susceptibility in a UK population.

Other factors: The consumption of meats, alcohol, and a low fruit and vegetable intake has been suggested as a potential risk factor for lung cancer, although findings are contradictory [66, 67]. There are well-established links between lung cancer and other lung diseases, notably Chronic Obstructive Pulmonary Disease (COPD) and idiopathic pulmonary fibrosis. There is also an excess risk of lung cancer in other inflammatory lung diseases, including prior tuberculosis, bronchiectasis and asthma. However, individuals can have multiple diagnostic labels e.g. COPD and bronchiectasis and the relative contribution of the lung disease compared to smoking and environmental exposure is poorly studied. Prior radiotherapy (RT) is yet another risk for LCINS, and it is evident that even regimes where lower volumes of lung are treated, eg adjuvant breast cancer, are associated with an excess risk of lung cancer.

Lung cancer screening. Randomised controlled trials provide conclusive evidence that screening higher risk smokers with low-dose computed tomography (LDCT) scans reduces lung cancer-specific mortality [68, 69]. These studies used age and a threshold of smoking exposure (e.g., ≥30 packyears) to select the screening population. However, the more precise targeting of screening, based on individually calculated lung cancer risk scores,

may improve screening performance [70, 71]. In the UK, the Targeted Lung Health Check (TLHC) programme has assessed the feasibility of LDCT screening implementation and led to the UK National Screening Committee formally recommending national adoption of targeted screening for lung cancer. Screening eligibility for this targeted programme is based on age (55–74 years) and individual risk score calculated using two risk prediction models PLCO_{M2012} [72] and LLP_{v2} [73]. Irrespective of other risk factors never smokers are not eligible for this programme.

At present there are no CT screening studies focussed on never smokers in Europe or North America. In Japan, one lung cancer screening programme demonstrated similar lung cancer detection in never smokers compared to smokers with less than 30 packyears smoking exposure [74]. In Taiwan, opportunistic LDCT screening has been promoted for several years. This has resulted in a 6-fold increase in early-stage disease detection in women (95% of whom are never smokers) and doubling of 5-year survival. However, there was no reduction in advanced lung cancer suggesting this approach is driving over-diagnosis rather than detection of clinically meaningful cancers [75]. The Taiwan Lung Cancer Screening for Never Smoker Trial (TALENT) is evaluating a targeted approach for LDCT screening in never smokers. Inclusion criteria included never smoking, age (55–75 years) and one of—family history of lung cancer (1st–3rd degree), passive smoking exposure, TB/COPD and high cooking index. A total of 12,011 individuals had a baseline LDCT scan. The prevalence of invasive lung cancer at baseline was 2.6% and 1.6% in those with and without a family history of lung cancer [76].

Modelling studies show that it is very challenging to identify never smokers at high risk [77] and previous reviews concluded that never smokers should not be screened as the benefits do not outweigh the potential risks such as radiation, over-diagnosis, unnecessary biopsies and treatment [78]. Therefore, novel approaches, driven by enrichment based on other risk factors or biomarkers are required.

Recommendation

- Establish a UK registry of patients with LCINS. This should leverage the existing national infrastructure within the National Health Service (NHS) for recording lung cancer cases, linked with other resources such as the National Lung Cancer Audit and Clinical Practice Research Datalink (CPRD), which may facilitate ‘high-level’ identification of risk factors.
- Establish a prospective cohort of patients diagnosed with LCINS to collect detailed demographics, medical/occupational history and risk factors. This cohort would be given the opportunity to consent for future in-depth surveys to establish individual environmental and occupational risks and comorbidities associated with LCINS. It would generate data representing the heterogeneous populations affected by LCINS including potentially under-represented groups (ethnicity, social deprivation). It would directly address the paucity of published large-scale data regarding UK LCINS populations.

The NHS/UK infrastructure is well suited to this approach. The successful development of a clinically and exposure annotated registry with paired archived samples and blood would allow molecular markers of germline risk and somatic mutational events to be related directly to exposure to putative environmental carcinogen (Theme 3). The objective would be to develop a risk score (based on demographics, exposure and molecular biomarkers) with a view to future stratification of a population for screening.

THEME 3: DISEASE BIOLOGY

Patient and public comments

The importance of further research to understand underlying biological mechanisms that play a role in the development of LCINS was highlighted—

‘...even if you move away from radon and live in a bubble of pure air, perfect diet, perfect fitness you may have a genetic mutation no one knows about.’

This might help address the ‘*why me?*’ question that often arises when a diagnosis of LCINS is made. ‘*The majority of the population is unaware that 1 in 2 of us will develop a cancer in our lifetime and then to develop a cancer that has only ever been associated with a lifestyle habit they’ve not had adds to their anger, fear and anxiety.*’

A deeper understanding of the pathobiology of LCINS could lead to strategies to prevent lung cancer and the development of more effective treatments. Identification of markers that identify aggressive disease or tumours with rapid tumour progression was mentioned in several questionnaires and how biomarkers might be used to promote earlier detection—

‘might molecular genetic biomarkers allow us to identify those at higher risk of lung cancer, for inclusion in cancer screening?’.

Evidence

A better understanding of the pathophysiology of LCINS has the potential to impact on the early detection and improved management of the disease. Most of the large-scale multi-omics studies on lung cancer have focused on the more common smoking-associated lung cancer in ever smokers. More recently, key studies have interrogated LCINS, drawing attention to the marked molecular differences between LCINS and ever smokers [79–82]. These studies have focused on adenocarcinoma, the dominant pathological subtype [83–86].

Broadly speaking three key observations have been made. The first is that the mutational signatures in LCINS are distinct from lung cancer in ever smokers (LCIES). The second is that the profile of mutational events affecting ‘driver’ oncogenes is different in LCINS and often involves druggable mutations. Finally, the genomic characteristics; tumour mutational burden (TMB) and aneuploidy are distinct in LCINS with a tendency towards a significantly less disrupted genome and a lower TMB in LCINS [79].

Mutational signatures in LCINS. Tobacco-smoking is associated with specific mutational signature, for example single-base substitution (SBS4) C > A/G > T. This was not detected in LCINS in one large survey and was infrequent in another [79, 87]. The important implication is that passive cigarette-smoking is not a dominant cause of LCINS. The data suggest some potential alternative endogenous and exogenous mechanisms.

Apolipoprotein B mRNA editing enzyme catalytic polypeptides (APOBECs) are a family of DNA-altering enzymes (cytosine deaminases) that target-specific sequence couplets for mutagenesis. In regions of East Asia (residents of Taiwan) where EGFR-mutated LCINS is common there is a suggestion that LCINS is associated with an APOBEC signature in younger females but has more of an exogenous mutational profile, including nitrated polycyclic hydrocarbons (perhaps from diesel exposure) in older females, observed in primarily stage 1 cancers [79]. In the Sherlock-Lung Study involving patients from the United States of European ancestry and those harbouring Stage 1–3 disease, a signature associated with reactive oxygen species was reported in 46% of cases, suggesting that oxidative stress may be a key genotoxic carcinogenic mechanism in LCINS [79].

Mutational hot-spots in LCINS. There are multiple mutational events regarded as key ‘drivers’ of lung carcinogenesis that are markedly enriched in LCINS compared to LCIES. The most common are EGFR mutations; others include ALK and ROS translocations and more rarely mutations in KRAS (G12C), BRAF, MET exon 14 skipping, ERBB2, AKT1 and NTRK [88, 89]. Some studies have attempted to describe potential links between certain occupational exposures

and driver mutations [90]. The treatment options are well reviewed [89] but the key message is that many LCINS have potentially actionable mutations [88]. We therefore recommend that comprehensive targeted sequencing of biopsies or alternatives e.g. ctDNA in LCINS is mandatory to guide treatment.

Somatic mutational signatures in both LCINS and LCIES vary with ethnicity and gender. LCINS has been particularly associated with South-East Asian ancestry, as discussed above. Importantly, recent evidence from a Latin American population showed that Native American ancestry is more important than environmental triggers in contributing to somatic mutational profiles [91]. Furthermore, ancestry can impact on the interpretation of tumour mutational burden and the efficacy of immuno-therapeutics [92].

More pertinent to LCINS in the UK population, Pirie et al reported an increased relative risk (RR) of LCINS in non-white compared to white women (RR = 2.34, 95% CI 1.55–3.52, $p < 0.001$) [55]. The predominance of LCINS in women has raised the possibility of a hormonal role in pathogenesis, although a mechanistic understanding remains elusive [93, 94].

Given the significant impact of gender and ancestry on LCINS incidence, somatic profiles and even potentially therapeutic response, there is a clear knowledge gap regarding the demographics and somatic profile of LCINS in the UK. Closing this gap through a targeted LCINS registry will aid the prevention of burgeoning health inequalities [81].

Genomic characteristics of LCINS. Cancers are characterised by disrupted genomes but there are significant differences between LCINS and LCIES. TMB is a biomarker that, with reservations, is associated with smoking and with predicted neoantigen burden and response to immunotherapy (IO) agents [80, 95, 96]. In the Sherlock-Lung study which reported on 232 LCINS patients [79], fresh-frozen tumour specimens were analysed using high-coverage whole genome sequencing. The TMB in LCINS was less than 1/7th of an LCIES cohort. Nevertheless, it is critical to acknowledge and understand the heterogeneity within LCINS and the implications for therapeutic efficacy [97]. The Sherlock group suggested 3 classifications of LCINS tumours; piano, forte and mezzo-forte based on differences in the cancer genome structure. Piano subtypes demonstrated a low mutational burden with infrequent whole genome doubling, a forte subtype with predominant whole genome duplication and mezzo-forte subtype enriched [79, 97] for chromosomal arm-level amplifications. HLA disruption was relatively rare, reported in only 5.7% of cases. Notably, those with mutated TP53 have elevated TMB and have been associated with reduced survival [98].

As well as TMB, cancer genomes typically exhibit structural variants such as whole genome doubling, somatic copy-number aberrations (SCNAs) and aneuploidy. However, in LCINS a significant proportion have a very 'quiet' genome with no detectable SCNAs (piano subtype) [79, 97]. This is consistent with the TMB data and reflects a fundamental difference between LCINS and LCIES.

The implications for precision oncology are significant. The biomarkers used to guide IO choices in LCIES are imperfect. Given IO is typically less effective in LCINS, further studies are needed to understand the mechanisms involved and to define those LCINS cases who may benefit from IO. For example, one suggestion from a Taiwanese cohort [80] was that APOBEC mutational signature status may predict with IO sensitivity in an EGFR-WT subgroup. The authors acknowledge the impact of germline/ancestry as well as country-specific environmental exposures on LCINS, reinforcing the need for a UK-specific approach.

Recommendation

- Establish a multicentre or UK patient registry/biobank for LCINS. This would describe the characteristics of the at-risk population in the UK. It would mandate the collection of

archived samples, or for centres with appropriate infrastructure, their prospective and longitudinal collection. The registry would be associated with a questionnaire to define demographics and environmental exposure (Theme 2). The intention would be to perform a deep-dive professional interview with as many patients with LCINS as possible to fully understand their potential exposure history.

As noted above this would have far-reaching impact. It would facilitate a range of studies including an in-depth analysis (pan-'omics) of the molecular epidemiology of UK LCINS and the interaction between environmental exposure, germline risk, interaction with microbiome and somatic events in LCINS. This dataset would inform whether there is a future potential for screening for LCINS in the UK a key aim of our patient population. It would provide an evidence base for experimental medicine approaches modelling and interplay between germline and environmental risks and directly inform novel target identification or target prioritisation for preclinical evaluation and therapeutic development for treatment or prevention. This would be a resource of immense interest to both academia and pharma and appropriate strategic partnerships could be launched.

THEME 4: LIVING WITH AND BEYOND

Patient and public comments

Of a number of discrete priorities that emerged, one participant questioned whether more could be done to educate people who continue to live with the disease and improve their standard of living through the assistance of specialists—

'Could the education (and quality of life) of patients living with & beyond lung cancer be improved with ongoing support, not just from clinical oncologists

Individuals queried whether exercise should be promoted following diagnosis, and treatment, with others highlighting the importance of exercise on improving lung function—

'Keeping active is evidenced to improve lung function... why is more not suggested to patients pre and post their treatment to remain as active as possible and increase activity to develop their lung function?'

Evidence

Firstly there was the confirmation of the importance of theme 1 and an emphasis that educating society in general and healthcare professionals in particular needs to continue beyond the diagnostic phase of the patient's journey, with the LCINS population having different needs and treatment options in comparison to those with smoking-related lung cancer.

While recognising that attitudes are changing and over the last 10 years there has been an improvement in the fatalistic view of a lung cancer diagnosis amongst oncologists, among the general public there remains a stigma associated with lung cancer diagnosis [99]. Most individuals agree with the statement '*lung cancer patients are at least partially to blame for their illness*', with half of people living with lung cancer experiencing blame from strangers and acquaintances and a quarter of individuals feeling less supported by family and friends [100]. Changing cultural and societal approaches to lung cancer stigma is challenging. Paradoxically the concerted efforts to improve awareness to stop smoking may have increased the stigma surrounding a lung cancer diagnosis impacting on support networks for these patients, further alienating those with LCINS who do not 'fit the profile' of a lung cancer patient.

There is little evidence about the specific needs and experiences of never smokers and therefore we have a limited understanding about whether they have different needs to

smokers or how best to support this group. The evidence relating to stigma and the unexpected diagnosis of lung cancer may impact on adjustment to a cancer diagnosis and lead to specific information needs. There is some suggestion that health-related quality of life (HRQoL) is better in those who quit smoking or are never smokers, with Rowland [101] suggesting that needs may be different and this warrants further investigation.

There is limited long-term data on survival of LCINS, some studies suggest that this population has a better outcome when compared to the smoking-related lung cancer population [12, 31, 102, 103]. This is despite presentation with vague symptoms and a lack of awareness of the possibility of a lung cancer diagnosis that means LCINS tend to present late with more advanced disease. While studies suggest around 66% presented with stage IV disease [48, 104] they do not show any clear difference when compared to the stage distribution seen in the smoking population [12].

Treatment

Treatment for LCINS should follow the same principles as those that guide the management of smoking-related lung cancer and all should be given the opportunity to participate in research studies. UK lung cancer trial recruitment figures show a 10-fold variation across the country [105]. This sits alongside the geographical variations seen in service, issues which need addressing for both the smoking and never smoking population. For those presenting with early-stage disease the focus needs to be on potentially curative treatment with surgery and/or radiotherapy. For the LCINS population knowledge of mutation and biomarker status is of crucial importance in guiding adjuvant systemic treatment [106–108].

Systemic therapy is the cornerstone of treatment for those presenting with advanced metastatic disease [109, 110]. It is within the systemic treatment setting that the approach to treatment is likely to differ most from that offered to the smoking population. In general, the LCINS population are younger with fewer co-morbidities at the time of diagnosis and better able to cope with the increased toxicity associated with multi-modality treatments [111, 112]. This population will also have a significantly higher levels of druggable driver mutations [6] for whom a sequential approach to systemic treatment may be more appropriate than using a combination treatment in the first line setting. Hence, it is particularly important that we move on from platinum-based chemotherapy to a more individualised approach to systemic treatment based on the results of rapid genomic testing at the time of diagnosis.

As discussed in Theme 3 there is a clear priority to develop new treatment for LCINS. However, it is equally important that we get a better understanding of the sequencing of those currently available (targeted, immunotherapy, chemotherapy) to limit/delay the development of tumour resistance [110, 113]. For example, the standard treatment approach for drugs targeted at mutation drivers is treat to progression where the resistant clones predominate and drive the course of the disease. An adaptive approach with drug 'holidays' or sequencing of drugs targeting different pathways to delay the emergence of the resistant clone have been proposed and studies evaluating this approach could be developed by investigator led groups.

The role of radiotherapy for the advanced LCINS population is also poorly understood. While palliative radiotherapy is widely used in stage IV NSCLC and has proven effective at controlling symptoms and may improve survival, the evidence comes from studies conducted in the last century. Since then, there have been major improvements in systemic therapies and it is increasingly recognised that in modern practice, palliative radiotherapy is still offered to many patients with advanced lung cancer, based on increasingly dated evidence. This is particularly true for the LCINS population who were barely represented in previous clinical trials and need

studies to test the timing, dose and fractionation of radiotherapy before, during or after modern systemic therapies.

Over the past two decades, there have been significant advances in radiotherapy planning and delivery, allowing higher dose treatments to be given more accurately, improving responses while reducing toxicity and there is the opportunity to develop specific arms in some of the current radiotherapy studies for palliative thoracic radiotherapy (TOURIST) [114], oligometastatic (SARON) (ClinicalTrials.gov identifier NCT02417662) or oligo-progressive (HALT) disease (ClinicalTrials.gov identifier NCT03256981).

Recommendations

There remains a stigma associated with a diagnosis of lung cancer, due to the well-established association with smoking. By addressing theme 1 and educating people of the risk factors associated with lung cancer among those who have never smoked, we may not only reduce this stigma, but also help to identify and diagnose LCINS earlier, aiding survival rates.

- As most of the research is around ever smokers, more research is needed to explore the views, needs, experiences and HRQoL of never smokers diagnosed with lung cancer. This will help identify differences in the support, informational and care needs of never smokers to develop or target evidence-based psychosocial interventions.
- Studies are required to identify the optimal methods for managing advanced lung cancer for the LCINS population focusing on patient support, adapting and integrating available treatment modalities. By doing so, we can help never smokers living with lung cancer by providing bespoke support if this differs from that of ever smokers.

CONCLUSIONS

We present a research strategy to address the unmet needs of patients diagnosed with lung cancer who have never smoked. Key recommendations-

1. Raising awareness of LCINS in the general population and with healthcare professionals, with a specific focus in primary care.
2. Develop a national registry for the LCINS population to further our understanding of the patient journey including barriers to diagnosis. The clinical and radiomic data collected should aim at evaluating inherited and environmental risks in the LCINS population to identify higher risk groups to prioritise for screening and develop approaches to improve disease prevention and earlier diagnosis. We also recommend establishing prospective cohorts with associated biological sample collection. The aim is to develop a resource to better characterise disease biology/genetic mutational changes aiding the development of more precise risk prediction and novel treatments.
3. Clinical trials are required to identify the optimal methods for managing advanced lung cancer in the never smoking patient population focusing on patient support, adapting and integrating available treatment modalities.

The NCRI is committed to supporting research to improve LCINS outcomes, maintaining a focus on LCINS as a key priority. This will entail an ongoing dialogue with patient advocates as well as strategic collaborations within academia and with biotech/pharma sectors.

DATA AVAILABILITY

Data is available upon request from the corresponding author.

REFERENCES

- Couraud S, Zalman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers—a review. *Eur J Cancer*. 2012;48:1299–311.
- Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. *Nat Rev Cancer*. 2007;7:778–90.
- Subramanian J, Govindan R. Lung cancer in never smokers: a review. *J Clin Oncol*. 2007;25:561–70.
- Bhopal A, Peake MD, Gilligan D, Cosford P. Lung cancer in never-smokers: a hidden disease. *J R Soc Med*. 2019;112:269–71.
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *Cancer J Clin*. 2005;55:74–108.
- Brenner DR, Hung RJ, Tsao MS, Shepherd FA, Johnston MR, Narod S, et al. Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. *BMC Cancer*. 2010;10:285.
- Rait G, Horsfall L. Twenty-year sociodemographic trends in lung cancer in non-smokers: a UK-based cohort study of 3.7 million people. *Cancer Epidemiol*. 2020;67:101771.
- Saito S, Espinoza-Mercado F, Liu H, Sata N, Cui X, Soukiasian HJ. Current status of research and treatment for non-small cell lung cancer in never-smoking females. *Cancer Biol Ther*. 2017;18:359–68.
- Cufari ME, Proli C, De Sousa P, Raubenheimer H, Al Sahaf M, Chavan H, et al. Increasing frequency of non-smoking lung cancer: Presentation of patients with early disease to a tertiary institution in the UK. *Eur J Cancer*. 2017;84:55–9.
- Pu X, Ye Y, Spitz MR, Wang L, Gu J, Lippman SM, et al. Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study. *Clin Cancer Res*. 2012;18:5983–91.
- McPhail S, Elliss-Brookes L, Shelton J, Ives A, Greenslade M, Vernon S, et al. Emergency presentation of cancer and short-term mortality. *Br J Cancer*. 2013;109:2027–34.
- ClementDuchene C, Stock S, Xu X, Chang ET, Gomez SL, West DW, et al. Survival among never-smokers with lung cancer in the cancer care outcomes research and surveillance study. *Ann Am Thorac Soc*. 2016;13:58–66.
- Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. *Br J Cancer*. 2015;112:S92–107.
- Swann R, McPhail S, Witt J, Shand B, Abel GA, Hiom S, et al. Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. *Br J Gen Pract*. 2018;68:e63–e72.
- Cassim S, Chepulis L, Keenan R, Kidd J, Firth M, Lawrenson R. Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review. *BMC Cancer*. 2019;19:25.
- Saab MM, Noonan B, Kilty C, FitzGerald S, Collins A, Lyng Å, et al. Awareness and help-seeking for early signs and symptoms of lung cancer: a qualitative study with high-risk individuals. *Eur J Oncol Nurs*. 2021;50:101880.
- Walter FM, Rubin G, Bankhead C, Morris HC, Hall N, Mills K, et al. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study. *Br J Cancer*. 2015;112:S6–13.
- Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. *Thorax*. 2005;60:1059–65.
- Swann R, Lyratzopoulos G, Rubin G, Pickworth E, McPhail S. The frequency, nature and impact of GP-assessed avoidable delays in a population-based cohort of cancer patients. *Cancer Epidemiol*. 2020;64:101617.
- Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP. Measures of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers. *Br J Cancer*. 2013;108:686–90.
- Lyratzopoulos G, Neal RD, Barbiere JM, Rubin GP, Abel GA. Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England. *Lancet Oncol*. 2012;13:353–65.
- Mendonca SC, Abel GA, Saunders CL, Wardle J, Lyratzopoulos G. Pre-referral general practitioner consultations and subsequent experience of cancer care: evidence from the English Cancer Patient Experience Survey. *Eur J Cancer Care (Engl)*. 2016;25:478–90.
- van Os S, Syversen A, Whitaker KL, Quaife SL, Janes SM, Jallow M, et al. Lung cancer symptom appraisal, help-seeking and diagnosis—rapid systematic review of differences between patients with and without a smoking history. *Psychooncology*. 2021;31:562–76.
- Dias M, Linhas R, Campinha S, Conde S, Barroso A. Lung cancer in never-smokers—what are the differences? *Acta Oncologica*. 2017;56:931–5.
- Lee JY, Na II, Jang SH, Hwang YI, Choe du H, Kim CH, et al. Differences in clinical presentation of non-small cell lung cancer in never-smokers versus smokers. *J Thorac Dis*. 2013;5:758–63.
- Nemesure B, Albano D, Nemesure A. Short- and long-term survival outcomes among never smokers who developed lung cancer. *Cancer Epidemiol*. 2021;75:102042.
- Tod AM, Craven J, Allmark P. Diagnostic delay in lung cancer: a qualitative study. *J Adv Nurs*. 2008;61:336–43.
- Carter-Harris L, Hermann CP, Schreiber J, Weaver MT, Rawl SM. Lung cancer stigma predicts timing of medical help-seeking behavior. *Oncol Nurs Forum*. 2014;41:E203–10.
- Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. *Chest*. 2007;132:185–92.
- Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. *Chest*. 2004;126:347–51.
- Yano T, Miura N, Takenaka T, Haro A, Okazaki H, Ohba T, et al. Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. *Cancer*. 2008;113:1012–8.
- Kennedy MPT, Cheyne L, Darby M, Plant P, Milton R, Robson JM, et al. Lung cancer stage-shift following a symptom awareness campaign. *Thorax*. 2018;73:1128–36.
- Ironmonger L, Ohuma E, Ormiston-Smith N, Gildea C, Thomson CS, Peake MD. An evaluation of the impact of large-scale interventions to raise public awareness of a lung cancer symptom. *Br J Cancer*. 2015;112:207–16.
- Saab MM, FitzGerald S, Noonan B, Kilty C, Collins A, Lyng Å, et al. Promoting lung cancer awareness, help-seeking and early detection: a systematic review of interventions. *Health Promot Int*. 2021;36:1656–71.
- Dubin S, Griffin D. Lung cancer in non-smokers. *Mo Med*. 2020;117:375–9.
- Humans IWGoEoCRt. Tobacco smoke and involuntary smoking. *IARC Monogr Eval Carcinog Risks Hum*. 2004;83:1–1438.
- Cheng ES, Egger S, Hughes S, Weber M, Steinberg J, Rahman B, et al. Systematic review and meta-analysis of residential radon and lung cancer in never-smokers. *Eur Respir Rev*. 2021;30:1–14.
- Darby S, Hill D, Auvinen A, Barros-Dios JM, Baysson H, Bochicchio F, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. *BMJ*. 2005;330:223.
- TorresDuran M, BarrosDios JM, FernandezVillar A, RuanoRavina A. Residential radon and lung cancer in never smokers. A systematic review. *Cancer Lett*. 2014;345:21–6.
- Loomis D, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, et al. The carcinogenicity of outdoor air pollution. *Lancet Oncol*. 2013;14:1262–3.
- Hill W, Lim EL, Weeden CE, Lee C, Augustine M, Chen K, et al. Lung adenocarcinoma promotion by air pollutants. *Nature*. 2023;616:159–67.
- Collaborators GBDRF. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392:1923–94.
- Turner MC, Krewski D, Pope ICA, Chen Y, Gapstur SM, Thun MJ. Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers. *Am J Respir Crit Care Med*. 2011;184:1374–81.
- Myers R, Brauer M, Dummer T, Atkar-Khattra S, Yee J, Melosky B, et al. High-ambient air pollution exposure among never smokers versus ever smokers with lung cancer. *J Thorac Oncol*. 2021;16:1850–8.
- Loomis D, Guha N, Hall AL, Straif K. Identifying occupational carcinogens: an update from the IARC Monographs. *Occup Environ Med*. 2018;75:593–603.
- Turner MC, Andersen ZJ, Baccarelli A, Diver WR, Gapstur SM, Pope CA 3rd, et al. Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations. *CA Cancer J Clin*. 2020. <https://doi.org/10.3322/caac.21632>. Epub ahead of print.
- Cancer IAfRo. IARC Working Group on the Identification of Carcinogenic Hazards to Humans. Opium Consumption. Lyon (FR): WHO; 2021.
- CasalMourino A, RuanoRavina A, TorresDuran M, ParenteLamelas I, Provencio-Pulla M, CastroAnon O, et al. Lung cancer survival in never-smokers and exposure to residential radon: results of the LCRINS study. *Cancer Lett*. 2020;487:21–6.
- Eckel SP, Cockburn M, Shu YH, Deng H, Lurmann FW, Liu L, et al. Air pollution affects lung cancer survival. *Thorax*. 2016;71:891–8.
- Kwak K, Kang D, Paek D. Environmental exposure to asbestos and the risk of lung cancer: a systematic review and meta-analysis. *Occup Environ Med*. 2022;79:207–14.
- Das A, Krishnamurthy A, Ramshankar V, Sagar TG, Swaminathan R. The increasing challenge of never smokers with adenocarcinoma lung: Need to look beyond tobacco exposure. *Indian J Cancer*. 2017;54:172–7.
- Turner MC. What is next for occupational cancer epidemiology? *Scand J Work Environ Health*. 2022;48:591–7.

53. Stücker I, Martin D, Neri M, Laurent-Puig P, Blons H, Antoine M, et al. Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank. *BMC Public Health*. 2017;17:324.
54. Hsu LH, Chu NM, Kao SH. Estrogen, estrogen receptor and lung cancer. *Int J Mol Sci*. 2017;18:1713.
55. Pirie K, Peto R, Green J, Reeves GK, Beral V. Lung cancer in never smokers in the UK Million Women Study. *Int J Cancer*. 2016;139:347–54.
56. Huang J, Yue N, Shi N, Wang Q, Cui T, Ying H, et al. Influencing factors of lung cancer in nonsmoking women: systematic review and meta-analysis. *J Public Health (Oxf)*. 2022;44:259–68.
57. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. *J Clin Oncol*. 2006;24:2245–51.
58. Corrales L, Rosell R, Cardona AF, Martin C, ZatarainBarron ZL, Arrieta O. Lung cancer in never smokers: The role of different risk factors other than tobacco smoking. *Crit Rev Oncol/Hematol*. 2020;148:102895.
59. Lebrecht MB, Crosbie EJ, Smith MJ, Woodward ER, Evans DG, Crosbie PAJ. Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors. *J Med Genet*. 2021;58:217–26.
60. Dai J, Lv J, Zhu M, Wang Y, Qin N, Ma H, et al. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. *Lancet Respir Med*. 2019;7:881–91.
61. Lan Q, Hsiung CA, Matsuo K, Hong YC, Seow A, Wang Z, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. *Nat Genet*. 2012;44:1330–5.
62. Wang Z, Seow WJ, Shiraishi K, Hsiung CA, Matsuo K, Liu J, et al. Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. *Hum Mol Genet*. 2016;25:620–9.
63. Izumi M, Suzumura T, Ogawa K, Matsumoto Y, Sawa K, Yoshimoto N, et al. Differences in molecular epidemiology of lung cancer among ethnicities (Asian vs. Caucasian). *J Thorac Dis*. 2020;12:3776–84.
64. Zhou W, Christiani DC. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. *Chin J Cancer*. 2011;30:287–92.
65. Berry DK, Wang X, Michalski ST, Kang HC, Yang S, Creelan BC, et al. Clinical cohort analysis of germline EGFR T790M demonstrates penetrance across ethnicities and races, sexes, and ages. *JCO Precis Oncol*. 2020;4. <https://doi.org/10.1200/PO.19.00297>.
66. Ko YH, Kim SJ, Kim W-S, Park CK, Park C-K, Suh Y-G, et al. Risk factors for primary lung cancer among never-smoking women in South Korea: a retrospective nationwide population-based cohort study. *Korean J Intern Med*. 2020;35:692–702.
67. GarciaLavandeira JA, RuanoRavina A, TorresDuran M, ParenteLamelas I, Provencio M, VarelaLema L, et al. Fruits and vegetables and lung cancer risk in never smokers. a multicentric and pooled case-control study. *Nutr Cancer*. 2022;74:613–21.
68. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. *N Engl J Med*. 2020;382:503–13.
69. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med*. 2011;365:395–409.
70. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. *N Engl J Med*. 2013;369:245–54.
71. Tammemagi MC, Ruparel M, Tremblay A, Myers R, Mayo J, Yee J, et al. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. *Lancet Oncol*. 2022;23:138–48.
72. Tammemagi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. *N Engl J Med*. 2013;368:728–36.
73. Field JK, Duffy SW, Baldwin DR, Whyne DK, Devaraj A, Brain KE, et al. UK lung cancer RCT pilot screening trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. *Thorax*. 2016;71:161–70.
74. Tammemagi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLS cohorts. *PLoS Med*. 2014;11:e1001764.
75. Kang HR, Cho JY, Lee SH, Lee YJ, Park JS, Cho YJ, et al. Role of low-dose computerized tomography in lung cancer screening among never-smokers. *J Thorac Oncol*. 2019;14:436–44.
76. Kakinuma R, Muramatsu Y, Asamura H, Watanabe SI, Kusumoto M, Tsuchida T, et al. Low-dose CT lung cancer screening in never-smokers and smokers: results of an eight-year observational study. *Transl Lung Cancer Res*. 2020;9:10–22.
77. Yang P. National lung cancer screening program in Taiwan: the TALENT Study. *J Thorac Oncol*. 2021;16:S58–S62.
78. Gao W, Wen CP, Wu A, Welch HG. Association of computed tomographic screening promotion with lung cancer overdiagnosis among Asian Women. *JAMA Intern Med*. 2022;182:283–90.
79. Zhang T, Joubert P, Ansari-Pour N, Zhao W, Hoang PH, Lokanga R, et al. Genomic and evolutionary classification of lung cancer in never smokers. *Nat Genet*. 2021;53:1348–59.
80. Chen YJ, Roumeliotis TI, Chang YH, Chen CT, Han CL, Lin MH, et al. Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression. *Cell*. 2020;182:226–44.e17.
81. Liang D, Wang J, Li D, Shi J, Jing J, Shan B, et al. Lung cancer in never-smokers: a multicenter case-control study in North China. *Front Oncol*. 2019;9:1354.
82. Couraud S, Debieuvre D, Moreau L, Dumont P, Margery J, Quoix E, et al. No impact of passive smoke on the somatic profile of lung cancers in never-smokers. *Eur Respir J*. 2015;45:1415–25.
83. Shan L, Zhang L, Zhu X, Wang Z, Fang S, Lin J, et al. Chinese never smokers with adenocarcinoma of the lung are younger and have fewer lymph node metastases than smokers. *Respir Res*. 2022;23:293.
84. Torres-Durán M, Curiel-García MT, Ruano-Ravina A, Provencio M, Parente-Lamelas I, Hernández-Hernández J, et al. Small-cell lung cancer in never-smokers. *ESMO Open*. 2021;6:100059.
85. Varghese AM, Zakowski MF, Yu HA, Won HH, Riely GJ, Krug LM, et al. Small-cell lung cancers in patients who never smoked cigarettes. *J Thorac Oncol*. 2014;9:892–6.
86. Huang Y, Wang R, Pan Y, Li H, Cheng C, Zheng D, et al. Clinical and genetic features of lung squamous cell cancer in never-smokers. *Oncotarget*. 2016;7:35979–88.
87. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. *Nature*. 2013;500:415–21.
88. Mack PC, Klein MI, Ayers KL, Zhou X, Guin S, Fink M, et al. Targeted next-generation sequencing reveals exceptionally high rates of molecular driver mutations in never-smokers with lung adenocarcinoma. *Oncologist*. 2022;27:476–86.
89. Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. *J Hematol Oncol*. 2021;14:108.
90. Paris C, Do P, Mastroianni B, Dixmier A, Dumont P, Pichon E, et al. Association between lung cancer somatic mutations and occupational exposure in never-smokers. *Eur Respir J*. 2017;50:10.
91. Carrot-Zhang J, Soca-Chafre G, Patterson N, Thorne AR, Nag A, Watson J, et al. Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations. *Cancer Discov*. 2021;11:591–8.
92. Nassar AH, Adib E, Abou Alaiwi S, El Zarif T, Groha S, Akl EW, et al. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. *Cancer Cell*. 2022;40:1161–72.e5.
93. Naoki Y, Kawaguchi T, Isa S-I, Shimizu S, Tamiya A, Asai K, et al. Molecular epidemiological study on passive smoking and estrogen receptor expression in never-smokers with non-small cell lung cancer. *Osaka City Med J*. 2016;62:77–84.
94. Szymanowska-Narloch A, Jassem E, Skrzypski M, Muley T, Meister M, Dienemann H, et al. Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients. *Adv Med Sci*. 2013;58:196–206.
95. Norum J, Nieder C. Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. *ESMO Open*. 2018;3:e000406.
96. Ruel LJ, Li Z, Gaudreault N, Henry C, Armero VS, Boudreau DK, et al. EP16.03-020 high tumor mutational burden by whole-genome sequencing in resected NSCLC in never smokers is associated with worse prognosis. *J Thorac Oncol*. 2022;17:5596–97.
97. de Alencar VTL, Figueiredo AB, Corassa M, Gollub KJ, Cordeiro de Lima VC. Lung cancer in never smokers: tumor immunology and challenges for immunotherapy. *Front Immunol*. 2022;13:984349.
98. Fan Z, Zhang Q, Feng L, Wang L, Zhou X, Han J, et al. Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer. *Ann Transl Med*. 2022;10:188.
99. Raleigh ZT. A biopsychosocial perspective on the experience of lung cancer. *J Psychosoc Oncol*. 2010;28:116–25.
100. Hamann HA, Williamson TJ, Studts JL, Ostroff JS. Lung cancer stigma then and now: continued challenges amid a landscape of progress. *J Thorac Oncol*. 2021;16:17–20.
101. Rowland C, Eiser C, Rowe R, Danson S. The effect of smoking on health-related quality of life in lung cancer patients: a systematic review. *BMJ Support Palliat Care*. 2012;2:312–8.

102. Kawaguchi T, Matsumura A, Fukai S, Tamura A, Saito R, Zell JA, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. *J Thorac Oncol.* 2010;5:1001–10.
103. Toh CK, Ong WS, Lim WT, Tan DS, Ng QS, Kanesvaran R, et al. A decade of never-smokers among lung cancer patients-increasing trend and improved survival. *Clin Lung Cancer.* 2018;19:e539–e50.
104. Muallaoglu S, Karadeniz C, Mertsoylu H, Besen AA, Sezer A, Sedef AM, et al. The clinicopathological and survival differences between never and ever smokers with non-small cell lung cancer. *J BUON.* 2014;19:453–8.
105. Clinical Research Network Study recruitment activity 2023. <https://www.nihr.ac.uk/NIHR> accessed Jun 2023.
106. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *N Engl J Med.* 2017;377:1919–29.
107. O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. *Lancet Oncol.* 2022;23:1274–86.
108. Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, et al. Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC. *J Thorac Oncol.* 2022;17:423–33.
109. Lee DH, Lee JS, Kim SW, RodriguesPereira J, Han B, Song XQ, et al. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. *Eur J Cancer.* 2013;49:3111–21.
110. Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, et al. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression $\geq 50\%$. *Ann Oncol.* 2020;31:404–11.
111. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med.* 2018;378:2078–92.
112. Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, et al. Atezolizumab in combination with carboplatin and Nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. *J Thorac Oncol.* 2020;15:1351–60.
113. Boye M, Wang X, Srimuninnimit V, Kang JH, Tsai CM, Orlando M, et al. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never-smoker patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer: quality of life results from a randomized phase III trial. *Clinical Lung Cancer.* 2016;17:150–60.
114. King J, Patel K, Woolf D, Hatton MQ. The use of palliative radiotherapy in the treatment of lung cancer. *Clin Oncol (R Coll Radiol).* 2022;34:761–70.

ACKNOWLEDGEMENTS

The authors would like to acknowledge the others who contributed presentations to the workshop—Martin Foster, Stephen Duffy, Serena Nik-Zainal, Sanjay Popat, Mary O'Brien and Fiona Blackhall. We would also like to thank Anna Fry who helped organise and guide the authors while writing the paper.

AUTHOR CONTRIBUTIONS

MH, FM and PC conceived and led the symposium and subsequent review supported by the NCRI Lung Cancer Studies Group. RH organised the conference and convened the writing group. LH/SK/DT performed a literature review, CP performed a search for relevant articles. LC/FM/CH/AR contributed to the initial manuscript, LH/SK/DT the subsequent revisions incorporating the literature review. FM/PC/MH edited the article. All authors reviewed and approved the final draft.

FUNDING

While this work received no specific funding; it was supported by the infrastructure of the NCRI. PAJC is supported by the NIHR Manchester Biomedical Research Centre (NIHR 203308). SK is supported by a NIHR Academic Clinical Lectureship in Medical Oncology. MCT is funded by a Ramón y Cajal fellowship (RYC-2017-01892) from the Spanish Ministry of Science, Innovation and Universities and co-funded by the European Social Fund. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the 'Centro de Excelencia Severo Ochoa 2019–2023' Programme (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Programme. RCR and FM are supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312) and RCR is supported by the Cancer Research UK Cambridge Centre CTRQR-2021\100012. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

COMPETING INTERESTS

SK: no competing interests to declare. NH: no competing interests to declare. DT: no competing interests to declare. RCR: Speaker honoraria from Inivata, Astra-Zeneca, Janssen, Olympus Medical, VJ Oncology. Research funding from Owlstone Medical, Victor Dahdaleh Charitable Foundation, Cancer Research UK, Asthma and Lung UK. CP: no competing interests to declare. LC: no competing interests to declare. FMcD: no competing interests to declare. CH: no competing interests to declare. AR: no competing interests to declare. MCT: no competing interests to declare. RAH: no competing interests to declare. JR: member of NCRI lung network and patient advocate forum, BTOG steering committee, ELF LC PAG, ERS LC task force, EORTC LC group and patient panel, UK LC CEG, NHSE lung screening advisory group. PAJC: no competing interests to declare. FMcC: has current laboratory research funding from Janssen Biotech and collaborations with AstraZeneca. MH: Speaker Honorarium from Boehringer Ingelheim, MSD, AstraZeneca, Takeda.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Consent was obtained for participation in the group events and for the results to be published as a review.

CONSENT FOR PUBLICATION

Consent for publication was sought from the authors of the paper.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Matthew Hatton.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.